Table 1.
Characteristics of Patients With AIC
| All Patients (N = 110) | AIC (n = 21) | No AIC (n = 89) | P Value | |
|---|---|---|---|---|
| Age at treatment, y | 57.5 (48.8–66.3) | 52.0 (46.5–59.0) | 58.0 (49.5–67.5) | 0.130 |
| Male | 50 (45.5) | 12 (57.1) | 38 (42.7) | 0.330 |
| Smoking history | 43 (39.1) | 12 (57.1) | 31 (34.8) | 0.082 |
| T-cell lymphoma | 10 (9.1) | 2 (9.5) | 8 (9.0) | 1.000 |
| Advanced stage, Ann Arbor III or IV | 80 (72.7) | 17 (81.0) | 63 (70.8) | 0.424 |
| Cumulative doxorubicin dosage, mg/m2 | 300.0 (240.0–300.0) | 300.0 (275.0–400.0) | 300.0 (240.0–300.0) | 0.088 |
| Radiation therapy | 15 (13.6) | 4 (19.1) | 11 (12.4) | 0.480 |
| Chest irradiation | 5 (4.5) | 1 (4.8) | 4 (4.5) | 1.000 |
| Auto-HSCT | 13 (11.8) | 5 (23.8) | 8 (9.0) | 0.124 |
Values are median (IQR) or n (%).
Group differences were analyzed using Wilcoxon test or Fisher’s exact test.
AIC = anthracycline-induced cardiotoxicity; Auto-HSCT = autologous hematopoietic stem cell transplantation.